Entrada Therapeutics, Inc.
TRDA
$6.09
-$0.70-10.31%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -66.80% | 5.74% | 63.38% | 146.92% | 451.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -66.80% | 5.74% | 63.38% | 146.92% | 451.22% |
| Cost of Revenue | 21.14% | 22.19% | 25.45% | 37.71% | 32.22% |
| Gross Profit | -142.99% | -24.42% | 193.44% | 84,207.08% | 415.82% |
| SG&A Expenses | 17.83% | 16.56% | 19.12% | 11.11% | 5.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.35% | 20.82% | 23.90% | 30.33% | 24.71% |
| Operating Income | -202.90% | -82.69% | 1,586.75% | 271.74% | 226.98% |
| Income Before Tax | -169.68% | -41.22% | 451.47% | 451.04% | 269.89% |
| Income Tax Expenses | -159.88% | -105.71% | -95.42% | -- | -65.90% |
| Earnings from Continuing Operations | -170.23% | 5.52% | 1,081.69% | 352.42% | 226.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -170.23% | 5.52% | 1,081.69% | 352.42% | 226.80% |
| EBIT | -202.90% | -82.69% | 1,586.75% | 271.74% | 226.98% |
| EBITDA | -195.24% | -70.73% | 15,920.56% | 297.65% | 235.89% |
| EPS Basic | -157.68% | 24.43% | 1,056.21% | 337.25% | 219.96% |
| Normalized Basic EPS | -157.27% | -29.02% | 469.80% | 431.31% | 259.31% |
| EPS Diluted | -160.55% | 26.24% | 837.20% | 310.46% | 214.86% |
| Normalized Diluted EPS | -159.33% | -31.23% | 482.58% | 408.10% | 253.72% |
| Average Basic Shares Outstanding | 22.00% | 17.56% | 12.83% | 8.84% | 4.79% |
| Average Diluted Shares Outstanding | 19.97% | 17.75% | 15.18% | 9.59% | 8.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |